Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $54.23, for a total transaction of $542,300.00. Following the sale, the insider now owns 92,231 shares in the company, valued at $5,001,687.13. This represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Catriona Yale also recently made the following trade(s):

• On Tuesday, June 10th, Catriona Yale sold 2,803 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total value of $151,362.00.
• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $39.30, for a total value of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The shares were sold at an average price of $37.91, for a total transaction of $343,957.43.

Akero Therapeutics Stock Performance

AKRO stock traded down $0.49 during trading hours on Friday, hitting $54.42. 253,464 shares of the stock were exchanged, compared to its average volume of 1,010,656. The firm has a market capitalization of $4.34 billion, a P/E ratio of -27.96 and a beta of -0.16. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $45.51 and a two-hundred day simple moving average of $40.94. Akero Therapeutics, Inc. has a 12 month low of $21.02 and a 12 month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup cut their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright increased their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $82.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AKRO. RTW Investments LP boosted its holdings in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Akero Therapeutics by 11.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock worth $194,997,000 after acquiring an additional 495,119 shares during the period. Vanguard Group Inc. increased its stake in shares of Akero Therapeutics by 14.2% in the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock worth $171,256,000 after purchasing an additional 526,233 shares in the last quarter. Deep Track Capital LP lifted its holdings in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Akero Therapeutics by 93.3% during the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after buying an additional 557,794 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.